Johnson & Johnson (JNJ) Falls 3.72% for February 05

Equities Staff |

One of the S&P 500’s big losers for Friday February 05 was Johnson & Johnson (JNJ). The company’s stock fell 3.72% to $100.04 on volume of 11.34 million shares.

The stock opened the day at 102.66 and traded between a low of $99.78 and a high of $102.77. The stock finished the day down $3.865 per share. Johnson & Johnson has an average daily volume of 8.54 million and a total float of 2.77 billion shares. The 50-day SMA for Johnson & Johnson is $101.38 and its 200-day SMA is $98.21. The high for the stock over the last 52 weeks is $105.49 and the low is $81.79.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson is centered in New Brunswick, NJ, and has 126,500 employees. Today’s trading day leaves the company with a market cap of $276.79 billion. The company has a P/S ratio of n/a, P/B ratio of 3.64, and a n/a.

For a complete fundamental analysis analysis of Johnson & Johnson, check out’s Stock Valuation Analysis report for JNJ. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Breathtec BioMedical Inc.

Breathtec Biomedical Inc is a medical diagnostics company. It is engaged in developing & commercializing breath analysis devices for the early detection of infections & life threatening diseases including cancers,…

Private Markets


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…